Form 8-K
March 03, 2016
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
CURRENT REPORT Pursuant to Section 13 or 15(d) of
Pursuant to Section 13 or 15(d) of
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2016
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Florida (State or other jurisdiction	001-33357	65-0643773 (IRS Employer	
of incorporation)	(Commission File Number)	Identification No.)	
2 Snunit Street Science Park, POB 455 Carmiel, Israel	20100		
(Address of principal execut	tive offices) (Zip Code)		
Registrant's telephone number, including area code +972-4-988-9488			
(Former name or former ad	dress, if changed since last r	eport.)	
** *	low if the Form 8-K filing is in the following provisions (see Ge	ntended to simultaneously satisfy the filing obligation of neral Instruction A.2. below):	
•		ecurities Act (17 CFR 230.425) ange Act (17 CFR 240.14a-12)	

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) "Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01. Other Events

On March 3, 2016, Protalix BioTherapeutics, Inc. (the "Company") issued a press release announcing that positive interim data from the Company's phase I/II dose-ranging clinical trial of PRX-102 for the treatment of Fabry disease will be presented on March 3, 2016 at 3:15 PM PT at the Lysosomal Disease Network 12th Annual WORLD*Symposium* 2016 in San Diego, CA. PRX-102 is a recombinant plant cell expressed, Pegylated modified version of the human alpha-Galactosidase-A enzyme. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated March 3, 2016

2

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: March 3, 2016 By: /s/ Yossi Maimon

Name: Yossi Maimon

Title: Vice President and Chief Financial Officer

3